This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large
by Zacks Equity Research
Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus
Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains
by Zacks Equity Research
The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.
Is Inovio Pharmaceuticals (INO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INO) Outperforming Other Medical Stocks This Year?
Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up
by Zacks Equity Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
Company News for Jan 31, 2020
by Zacks Equity Research
Companies In The News Are: BGG, INO, MDLZ, MGEN
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus Spooks Global Markets: Winners and Losers
by Zacks Equity Research
So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs
by Indrajit Bandyopadhyay
Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.
Implied Volatility Surging for Inovio (INO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Merck's Ebola Vaccine Ervebo Gets Approval in United States
by Zacks Equity Research
FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.
Inovio (INO) Up 14.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
by Zacks Equity Research
Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Merck's Ebola Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
by Zacks Equity Research
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio (INO) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -7.14% and -97.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.